20/20 Biolabs Inc Financials
This page shows 20/20 Biolabs Inc (AIDX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 2 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
A small revenue base is still not covering the fixed operating cost structure, so cash support comes mainly from financing.
From FY2024 to FY2025, operating losses and cash burn both narrowed, showing costs were cut faster than sales expanded. But liquidity weakened anyway: the current ratio fell to 0.6x and equity slipped to-$19K , which means a leaner income statement still has not become a self-funding balance sheet. That is the pattern of a business improving its burn rate without yet rebuilding financial slack.
Loss reduction came more from cost discipline than from scale. Gross margin rose to
The balance sheet now looks tighter even though the business is burning less cash. Current assets of
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of 20/20 Biolabs Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
20/20 Biolabs Inc has an operating margin of -162.9%, meaning the company retains $-163 of operating profit per $100 of revenue. This below-average margin results in a low score of 23/100, suggesting thin profitability after operating expenses. This is up from -324.0% the prior year.
20/20 Biolabs Inc's revenue surged 16.7% year-over-year to $2.0M, reflecting rapid business expansion. This strong growth earns a score of 78/100.
20/20 Biolabs Inc has a moderate D/E ratio of -216.21. This balance of debt and equity financing earns a leverage score of 39/100.
20/20 Biolabs Inc's current ratio of 0.60 is below the typical benchmark, resulting in a score of 7/100. This tight liquidity could limit financial flexibility if cash inflows slow.
20/20 Biolabs Inc scores -12.79, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($6.3M) relative to total liabilities ($4.2M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
20/20 Biolabs Inc passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
For every $1 of reported earnings, 20/20 Biolabs Inc generates $0.51 in operating cash flow (-$1.9M OCF vs -$3.7M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
20/20 Biolabs Inc earns $-21.3 in operating income for every $1 of interest expense (-$3.3M vs $156K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
20/20 Biolabs Inc generated $2.0M in revenue in fiscal year 2025. This represents an increase of 16.7% from the prior year.
20/20 Biolabs Inc's EBITDA was -$3.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 41.2% from the prior year.
20/20 Biolabs Inc reported -$3.7M in net income in fiscal year 2025. This represents an increase of 32.7% from the prior year.
20/20 Biolabs Inc earned $-0.76 per diluted share (EPS) in fiscal year 2025. This represents an increase of 34.5% from the prior year.
Cash & Balance Sheet
20/20 Biolabs Inc held $1.0M in cash against $0 in long-term debt as of fiscal year 2025.
20/20 Biolabs Inc had 5M shares outstanding in fiscal year 2025. This represents an increase of 12.8% from the prior year.
Margins & Returns
20/20 Biolabs Inc's gross margin was 29.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 9.0 percentage points from the prior year.
20/20 Biolabs Inc's operating margin was -162.9% in fiscal year 2025, reflecting core business profitability. This is up 161.1 percentage points from the prior year.
20/20 Biolabs Inc's net profit margin was -182.8% in fiscal year 2025, showing the share of revenue converted to profit. This is up 134.0 percentage points from the prior year.
Capital Allocation
20/20 Biolabs Inc invested $593K in research and development in fiscal year 2025. This represents a decrease of 53.0% from the prior year.
AIDX Income Statement
| Metric | Q1'26 | Q4'25 | Q1'25 | Q4'24 |
|---|---|---|---|---|
| Revenue | $353K | N/A | $554K | N/A |
| Cost of Revenue | $290K | N/A | $388K | N/A |
| Gross Profit | $63K | N/A | $166K | N/A |
| R&D Expenses | $153K | N/A | $137K | N/A |
| SG&A Expenses | $1.4M | N/A | $801K | N/A |
| Operating Income | -$1.4M | N/A | -$772K | N/A |
| Interest Expense | $267K | N/A | $740 | N/A |
| Income Tax | N/A | N/A | N/A | N/A |
| Net Income | -$2.2M | N/A | -$765K | N/A |
| EPS (Diluted) | $-0.28 | N/A | $-0.16 | N/A |
AIDX Balance Sheet
| Metric | Q1'26 | Q4'25 | Q1'25 | Q4'24 |
|---|---|---|---|---|
| Total Assets | $5.8M+40.3% | $4.1M | N/A | $3.6M |
| Current Assets | $4.7M+219.5% | $1.5M | N/A | $2.0M |
| Cash & Equivalents | $4.2M+311.2% | $1.0M-34.1% | $1.6M-12.7% | $1.8M |
| Inventory | $105K-10.1% | $116K | N/A | $47K |
| Accounts Receivable | $201K+0.8% | $200K | N/A | $135K |
| Goodwill | N/A | N/A | N/A | N/A |
| Total Liabilities | $3.0M-26.7% | $4.2M | N/A | $2.1M |
| Current Liabilities | $2.6M+4.7% | $2.5M | N/A | $1.4M |
| Long-Term Debt | N/A | N/A | N/A | N/A |
| Total Equity | $2.6M+13379.0% | -$19K-101.8% | $1.1M-29.4% | $1.5M |
| Retained Earnings | -$35.4M-6.5% | -$33.2M | N/A | -$29.5M |
AIDX Cash Flow Statement
| Metric | Q1'26 | Q4'25 | Q1'25 | Q4'24 |
|---|---|---|---|---|
| Operating Cash Flow | -$1.3M | N/A | -$488K | N/A |
| Capital Expenditures | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A |
| Investing Cash Flow | -$5K | N/A | N/A | N/A |
| Financing Cash Flow | $4.5M | N/A | $262K | N/A |
| Dividends Paid | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A |
AIDX Financial Ratios
| Metric | Q1'26 | Q4'25 | Q1'25 | Q4'24 |
|---|---|---|---|---|
| Gross Margin | 17.8% | N/A | 29.9% | N/A |
| Operating Margin | -408.5% | N/A | -139.4% | N/A |
| Net Margin | -615.4% | N/A | -138.1% | N/A |
| Return on Equity | -85.2% | N/A | -71.9% | N/A |
| Return on Assets | -37.5% | N/A | N/A | N/A |
| Current Ratio | 1.82+1.2 | 0.60 | N/A | 1.50 |
| Debt-to-Equity | 1.19+217.4 | -216.21 | N/A | 1.38 |
| FCF Margin | N/A | N/A | N/A | N/A |
Note: Shareholder equity is negative (-$19K), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.60), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Frequently Asked Questions
What is 20/20 Biolabs Inc's annual revenue?
20/20 Biolabs Inc (AIDX) reported $2.0M in total revenue for fiscal year 2025. This represents a 16.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is 20/20 Biolabs Inc's revenue growing?
20/20 Biolabs Inc (AIDX) revenue grew by 16.7% year-over-year, from $1.8M to $2.0M in fiscal year 2025.
Is 20/20 Biolabs Inc profitable?
No, 20/20 Biolabs Inc (AIDX) reported a net income of -$3.7M in fiscal year 2025, with a net profit margin of -182.8%.
What is 20/20 Biolabs Inc's EBITDA?
20/20 Biolabs Inc (AIDX) had EBITDA of -$3.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is 20/20 Biolabs Inc's gross margin?
20/20 Biolabs Inc (AIDX) had a gross margin of 29.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is 20/20 Biolabs Inc's operating margin?
20/20 Biolabs Inc (AIDX) had an operating margin of -162.9% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is 20/20 Biolabs Inc's net profit margin?
20/20 Biolabs Inc (AIDX) had a net profit margin of -182.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is 20/20 Biolabs Inc's operating cash flow?
20/20 Biolabs Inc (AIDX) generated -$1.9M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are 20/20 Biolabs Inc's total assets?
20/20 Biolabs Inc (AIDX) had $4.1M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does 20/20 Biolabs Inc spend on research and development?
20/20 Biolabs Inc (AIDX) invested $593K in research and development during fiscal year 2025.
What is 20/20 Biolabs Inc's current ratio?
20/20 Biolabs Inc (AIDX) had a current ratio of 0.60 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is 20/20 Biolabs Inc's debt-to-equity ratio?
20/20 Biolabs Inc (AIDX) had a debt-to-equity ratio of -216.21 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is 20/20 Biolabs Inc's return on assets (ROA)?
20/20 Biolabs Inc (AIDX) had a return on assets of -90.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is 20/20 Biolabs Inc's cash runway?
Based on fiscal year 2025 data, 20/20 Biolabs Inc (AIDX) had $1.0M in cash against an annual operating cash burn of $1.9M. This gives an estimated cash runway of approximately 6 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is 20/20 Biolabs Inc's debt-to-equity ratio negative or unusual?
20/20 Biolabs Inc (AIDX) has negative shareholder equity of -$19K as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is 20/20 Biolabs Inc's Altman Z-Score?
20/20 Biolabs Inc (AIDX) has an Altman Z-Score of -12.79, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is 20/20 Biolabs Inc's Piotroski F-Score?
20/20 Biolabs Inc (AIDX) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are 20/20 Biolabs Inc's earnings high quality?
20/20 Biolabs Inc (AIDX) has an earnings quality ratio of 0.51x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can 20/20 Biolabs Inc cover its interest payments?
20/20 Biolabs Inc (AIDX) has an interest coverage ratio of -21.3x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is 20/20 Biolabs Inc?
20/20 Biolabs Inc (AIDX) scores 29 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.